T-pred is the new generation, proprietary combination drug product designed and formulated by ISTA Pharmaceuticals Inc., putting together a couple of existing most effective ingredients called Tobramycin and Prednisolone Acetate to be used for the treatment of Ocular Inflammation conditions for which the corticosteroid is yet prescribed and where the bacterial ocular infections exist. ISTA Pharmaceuticals Inc. has filed the for the Investigational New Drug application – IND, to start phase 3 studies for the new eye drops, designated T-pred, to be used as the prescription treatment therapy of steroid responsive ocular inflammation where probabilities of bacterial infections subsists. However, it is reported that ISTA Pharmaceuticals Inc. was given the ‘not-approvable’ letter by the United States Food and Drugs Administration authorities because the clinical trial did not meet the expected parameters.

The randomly conducted, dual-masked U.S. FDA phase 3 trials at multiple centers successfully attained the preliminary parameters, duly exhibiting bioequivalence of Prednisolone Acetate between ISTA Pharmaceuticals’ combination product T-pred with Prednisolone Acetate 1.0% and Tobramycin 0.3%. The proportions of application of Prednisolone Acetate required ascertaining bioequivalence must come down between 80% and 125% with 90% assurance, for exhibiting that the both of the products were bioequivalent. This combination product T-pred of ISTA Pharmaceuticals Inc. attained or even surpassed its target both in the objective to treat as well as the per-protocol patient populations.     

T-pred containing Tobramycin with Prednisolone Acetate - the combination product of ISTA Pharmaceuticals Inc., if gets the formal recognition by the United States Foods and Drugs Administration authorities,, is likely to contend in the antibiotic steroid segment of the United States relevant ophthalmic anti-inflammatory markets.